Schultz’ Controversial Approval Of Cyberonics Device Has Little Precedent
This article was originally published in The Gray Sheet
Executive Summary
CDRH Director Dan Schultz's decision to override device and drug center review staff to approve Cyberonics' VNS Therapy neurostimulation device for treatment-resistant depression has scant precedent in recent history. All the same, he appears to have followed established FDA procedures